Prognostic value of serum vascular endothelial growth factor (VEGF) and plasma activity of matrix metalloproteinase (MMP) 2 and 9 in lymphoma-affected dogs

Gentilini, Fabio; Calzolari, C; Turba, María Elena; Agnoli, Chiara; Fava, Davide; Forni, Monica; Bergamini, Paolo Famigli

doi:10.1016/j.leukres.2005.04.005

Cited by 42 publications

(45 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Plasma and serum levels of VEGF have been demonstrated to increase in human patients with malignant tumors, and this has been suggested to be a prognostic indicator in these cases [1,6,7,9,12,17,22]. Recently, some studies have demonstrated that when compared with healthy dogs, the level of circulating VEGF in dogs with malignant tumors is significantly increased [2,5,10,[19][20][21]. Additionally, immunohistopathological overexpression of VEGF and its receptor has been reported in mammary gland tumor (MGT), seminoma, and squamous cell carcinoma [8,[13][14][15].…”

mentioning

confidence: 99%

“…Additionally, immunohistopathological overexpression of VEGF and its receptor has been reported in mammary gland tumor (MGT), seminoma, and squamous cell carcinoma [8,[13][14][15]. However, no studies have focused on the clinical significance of circulating VEGF as an indicator of prognosis in tumor-bearing dogs except for dogs with lymphomas [5]. If the prognosis of canine MGT cases can be estimated by the measurement of circulating VEGF level, adjuvant therapy, including chemotherapy and/ or radiation therapy, could be accompanied with surgery; this may improve the survival time or disease-free time in case with poor prognosis.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Clinical Significance of Circulating Vascular Endothelial Growth Factor in Dogs with Mammary Gland Tumors

et al. 2007

View full text Add to dashboard Cite

ABSTRACT. Increase in circulating vascular endothelial growth factor (VEGF) is suggested as a prognostic indicator in human patients with malignant tumors. The purpose of this study was to evaluate the clinical significance of circulating VEGF in dogs with mammary gland tumors (MGT). Both plasma and serum VEGF were significantly higher in dogs with MGT when compared with those in the healthy dogs. In dogs with MGT, the plasma and serum VEGF of the malignant group increased significantly compared with those of the benign group. Additionally, there was a significant difference between the plasma and serum VEGF in the groups with postoperative metastasis and no metastasis. Circulating VEGF is expected to be clinically available for the determination of prognosis in canine MGT. KEY WORDS: canine, mammary gland tumor, vascular endothelial growth factor.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Clinical Significance of Circulating Vascular Endothelial Growth Factor in Dogs with Mammary Gland Tumors

et al. 2007

View full text Add to dashboard Cite

show abstract

“…In a previous study, changes from 0 to 23.28 pg/mL were observed in healthy dogs and from 0 to 189.84 pg/mL in dogs with lymphoma (GENTILINI et al, 2005). The lack of a correlation between VEGF serum concentration and VEGF immunostaining show that circulating levels of VEGF do not reflect the tumor microenvironment.…”

Section: Discussionmentioning

confidence: 89%

“…Salven et al (2000) showed no correlation between serum concentrations of VEGF and the clinical stage of human non-Hodgkin's lymphomas. In a study using dogs, a significant correlation between VEGF serum levels and substage "b" lymphomas was found (GENTILINI et al, 2005). Wolfesberger et al (2008) reported significantly higher VEGF plasma levels in dogs with T-cell lymphoma and high-grade malignant lymphomas.…”

Section: Discussionmentioning

confidence: 98%

“…In dogs, VEGF expression is evident in malignant mammary gland tumor (MAIOLINO et al, 2000), squamous cell carcinoma (RESTUCCI et al, 2003), poorly differentiated seminoma (MILLANTA et al, 2006), meningioma (PLATT et al, 2006), mast cell tumor (REBUZZI et al, 2007), oral melanoma (TAYLOR et al, 2007) and lymphoma (WOLFESBERGER et al, 2008) cells. Studies have shown elevated plasma concentrations of VEGF in dogs with hemangiosarcoma and lymphoma (CLIFFORD et al, 2001;GENTILINI et al, 2005;ARESU et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum concentration and immunostaining of vascular endothelial growth factor in dogs with multicentric lymphoma

Rodigheri

Calazans

Amorim³

et al. 2015

Sem. Ci. Agr.

View full text Add to dashboard Cite

Vascular endothelium growth factor (VEGF) is one of the most specific regulators of tumor angiogenesis and lymphangiogenesis. Moreover, VEGF plays a role in tumorigenesis through activation of an autocrine signaling pathway that enables cancer cells to stimulate their own growth. The aim of this study was to investigate VEGF serum levels and immunoexpression in canine multicentric lymphomas and correlate these parameters with the prognostic factors of this cancer. Sixteen dogs were evaluated (eight clinically healthy and eight diagnosed with multicentric lymphoma). The animals underwent blood sampling to measure VEGF serum concentrations and lymph node biopsy to evaluate VEGF immunoexpression. The VEGF immunoreactivity score was higher (p=0.0003) in the lymph nodes of dogs with multicentric lymphoma (8.50±2.33) than in those of healthy dogs (1.87±1.80). There was no significant difference in the VEGF serum concentrations between healthy dogs and dogs with lymphoma (p=0.08). Immunophenotype, clinical stage and grade of malignancy influenced the life expectancy of dogs with lymphoma. Our results showed that VEGF is expressed in high amounts in the lymph nodes of dogs with multicentric lymphoma and may be responsible for the growth, survival and migration of tumor cells.

show abstract

Neoangiogenesis markers in canine urothelial carcinomas: A cross‐sectional study

Gentilini,

Salaroli,

Tornago

et al. 2024

Veterinary Medicine & Sci

Self Cite

View full text Add to dashboard Cite

BackgroundIn humans, there is a growing body of evidence that neoangiogenesis is crucial for tumour growth and progression in urothelial carcinomas (UC) which also typically exhibit overactivation of the RAS‐MAPK pathway. In canine UC (cUC), the same pathway has been aberrantly activated due to V595E BRAF variant and BRAF inhibitors has been evaluated as more effective treatment. However, BRAF inhibition is hampered in humans by rapidly occurring of chemoresistance. Targeting angiogenesis has been speculated to increase the effectiveness of BRAF inhibitors and to delay the development of chemoresistance.ObjectivesThis study aimed to investigate the level of angiogenic markers in urine samples of UC affected dogs (n = 15) in comparison to an unmatched control group (n = 16) along with the clinical, morphological and molecular features.MethodsIn urine, both vascular endothelial growth factor (VEGF) concentration, using an ELISA assay, and MMP2 and 9 activities, using the zymographic assay, were measured. BRAF analysis was carried out using a digital PCR method.ResultsUrinary VEGF concentration (mean pg/g_uCrea 6.9 ± 27.7 vs. 1074 ± 1797, p < 0.01) and MMP activity (mean 6.8 × 106 ± 9.2 × 106 vs. 2.5 × 107 ± 2.3 × 107, p < 0.05) were higher in affected dogs than in healthy controls. Urinary active MMP9 was significantly correlated with T3 stage, it was absent in dogs with undetectable VEGF and it correlated well with urinary VEGF concentration. In this cohort, 10/10 UC affected dogs exhibited the V595E BRAF variation.ConclusionThe findings are consistent with the presence of overactive neoangiogenesis in cUC. Urinary active MMP9 may be suitable for use as tumour progression biomarker. The addition of angiogenesis targeting may be rationale for novel therapeutic strategies.

show abstract

Prognostic value of serum vascular endothelial growth factor (VEGF) and plasma activity of matrix metalloproteinase (MMP) 2 and 9 in lymphoma-affected dogs

Cited by 42 publications

References 25 publications

Clinical Significance of Circulating Vascular Endothelial Growth Factor in Dogs with Mammary Gland Tumors

Clinical Significance of Circulating Vascular Endothelial Growth Factor in Dogs with Mammary Gland Tumors

Serum concentration and immunostaining of vascular endothelial growth factor in dogs with multicentric lymphoma

Neoangiogenesis markers in canine urothelial carcinomas: A cross‐sectional study

Contact Info

Product

Resources

About